Zimmer Biomet Bought Time — Then Monogram's Clock Jumped a Year Forward
A half-point organic raise is the least interesting thing in this print: the autonomous robot arrives early, the knee story refuses to die, and the stock has already run 28%.
ZBH · Earnings Call · 2026-11-04
The tape voted before the transcript was written
Zimmer Biomet's stock has risen 27.9% over the last 90 trading days — a single, unbroken uptrend from the June 30 low, with no drawdown worth mentioning. That is the tape of a company where something good has already been decided. It is also still roughly 36% below the April 2021 peak of $173.27, which tells you how much of this move is repair rather than discovery.
So what is the market paying for? The guidance raise alone does not explain a 28% rally: organic constant-currency growth went from 2.25%–3.25% to 3.0%–3.5%, and adjusted EPS guidance moved from $8.47–$8.59 to $8.50–$8.60 — a two-cent midpoint bump. The likelier culprit surfaced in Larry Biegelsen's question about media reports of private equity interest in orthopaedic assets. Ivan Tornos did not deny anything; he simply refused to engage.
Obviously, I'm not going to get into a lot of speculation around the deals that are happening elsewhere. What I'll tell you is that our employees are laser-focused on driving growth.
That is the honest answer, and also the reason the stock is where it is. When a medtech trades in the low-teens multiple of free cash flow, financial-sponsor interest is a plausible catalyst, and management's non-denial keeps it alive. But an M&A bid is not an operating story. The operating story is elsewhere on the call.
What genuinely changed: the regulatory clock on Monogram
Six quarters ago, on the August 2025 call, the sequencing was explicit and conservative: a semi-autonomous launch first, then autonomy later.
“semi-autonomous will launch in early '27. We believe that fully autonomous mBôs will launch in late 2027, if not early 2028.” — Ivan Tornos, Chairman, President and CEO · 2025-08-07
On this call, that staircase collapsed into a single step. The company now expects to file the 510(k) "very, very soon" for a fully autonomous system and to launch in the first half of 2027 — a year ahead of the original fully-autonomous expectation, and without the semi-autonomous intermediate.
“given the clinical work that we've done around validation and verification, we can actually leap forward to a fully autonomous indication.” — Ivan Tornos, Chairman, President and CEO · 2026-11-04
The commercial logic rests on a genuinely large pool: roughly 80% of U.S. surgeons and 90% outside the U.S. do not use a robot at all. Ivan called this the blue ocean opportunity, and the pitch is deliberately procedural rather than technological — that the system avoids forcing a complex surgical algorithm on the surgeon, cuts bone in under three minutes, and requires no CT scan for markets where CT is neither reimbursed nor desired. That last point matters because CT scan was the company's single highest-ranked theme just one quarter ago, when the whole robotics pitch was framed around the suite rather than a specific autonomous platform. The autonomous robot theme, which spiked to the top of the company's keyword list back in Q3 2025, has finally migrated from aspiration to filing.
There is real risk here that the market is skipping over: a 510(k) submission is not an approval, and Ivan said so twice unprompted.
The raise is small; the margin number is the tell
Revenue of $2.63 billion grew 3.1% reported and 3.7% constant currency, or 4.7% excluding the China distributor consolidation. Two-thirds of the book grew upper-single or double-digit: Hips +7%, S.E.T. +7.1%, technology and data +13%, and robotics/data/AI +20%. Paragon 28 grew over 18%. Knees fell 2.6%.
What pays for all that is margin. Adjusted gross margin was 71.7%, down 90 basis points; adjusted operating margin 25.1%, down 140 basis points, with the full year guided to a decline of a little more than 50 basis points. The company's GAAP operating margin sits at 15.0%, versus a 24.8% peak set back in 2014 — a 42% drawdown from that high-water mark. That gap is the entire strategic case for the cost programme announced here: closing underutilised U.S. manufacturing sites and consolidating into Warsaw, an India global capability centre, AI process partners, and a cost base that is still, in Ivan's words, "roughly 46%" of sales against a $3.8 billion OpEx pool of which $1 billion is variable compensation.
The commercial execution deficit remains the named culprit for the knee problem — “probably 90% of our underperformance expected, but underperformance in knees is commercial execution driven” — Ivan Tornos, Chairman, President and CEO · 2026-11-04 — and the sales-force rebuild is now three quarters into an eight-quarter journey, with over 75% of the U.S. force dedicated and the riskiest third stage just beginning.
The China cliff has a date printed on it
Buried in the raise is the cleanest setup for 2027: the China distributor reset cost 100 basis points in Q3, will cost another 100 in Q4, and 50 for the full year — and it anniversaries in January.
“China is 2% of the revenue of the company, 1% of the EBITDA of the company, but it's been declining at massive rates in 2026.” — Ivan Tornos, Chairman, President and CEO · 2026-11-04
Add a full year of Paragon 28 organic growth, plus Monogram, and you have three mechanical tailwinds for next year that require no market acceleration at all. That is why the muted price reaction to a muted raise is defensible — the 2027 bridge is arithmetic, not hope.
What went quiet
The most revealing thing on this call is what vanished. restorative therapy was the company's number-one keyword in Q4 2025, discussed at length as a $110–120 million business where “we didn't budget adequately. So that's a mistake we're not going to repeat.” — Ivan Tornos, Chairman, President and CEO · 2025-11-05 This quarter it merited one clause — "declined in the quarter as expected" — and not a single analyst asked. Likewise the emerging-market distributor cancellations that cost 120 basis points in Q3 2025 and were deliberately excluded from guidance: “So we took that out of the guidance.” — Ivan Tornos, Chairman, President and CEO · 2025-11-05 No mention this quarter. Those themes are gone, not because they were fixed with fanfare, but because they are now small enough not to matter — a quiet, useful form of resolution.
What replaced them is the framing Ivan is now pushing hardest: we are no longer just a knee company, with global knees down to roughly a third of the book and U.S. knees around 20%. It is a fair point and a well-worn one — and yet Global knees were still the single largest drag on the quarter. The framing only becomes true when the knee stops being the reason the guidance is where it is.
The cash engine, at least, is not in question: free cash flow of $372 million in the quarter, up 34%, with full-year growth guided to 9%–11% and roughly $1 billion of buybacks. At the July quarter-end the stock traded at about 11.7x price to free cash flow on a free cash flow base that has more than recovered its 2022 collapse. The rally has lifted that multiple, but not to a level that embarrasses the franchise.
The bottom line
Zimmer Biomet is a company whose stock has already priced in a better 2027, on a combination of a dated China cliff, a robot that just got faster through the FDA queue, and a persistent private-equity rumour it will neither confirm nor deny. The operating evidence is respectable but not transformative: mid-single-digit growth with two-thirds of the portfolio compounding, offset by a knee franchise that management concedes is self-inflicted and a margin line still 140 basis points worse than a year ago. The interesting question is no longer whether the knee recovers — it is whether the blue ocean of non-robotic surgeons, the ASC migration flagged across this week's site of care commentary, and a cost base at 46% of sales can together produce the six-percent weighted market growth rate management has now put a decade-end date on.